Chronic nicotine alters NO signaling of Ca(2+) channels in cerebral arterioles

Circ Res. 2001 Feb 16;88(3):359-65. doi: 10.1161/01.res.88.3.359.

Abstract

Smoking is a major health hazard with proven deleterious effects on the cerebral circulation, including a decrease in cerebral blood flow and a high risk for stroke. To elucidate cellular mechanisms for the vasoconstrictive and pathological effects of nicotine, we used a nystatin-perforated patch-clamp technique to study Ca(2+) channels and Ca(2+)-activated K(+) (BK) channels in smooth muscle cells isolated from cerebral lenticulostriate arterioles of rats chronically exposed to nicotine (4.5 mg/kg per day of nicotine free base, 15 to 22 days via osmotic minipump). Two major effects were observed in cells from nicotine-treated animals compared with controls. First, Ca(2+) channels were upregulated (0.48+/-0.03 pS/pF [20 cells] versus 0.35+/-0.01 pS/pF [31 cells], P:<0.005) and BK channels were downregulated (12+/-3 pA/pF [14 cells] versus 34+/-7 pA/pF [14 cells], P:<0.05), mimicking the effect of an apparent decrease in bioavailability of endogenous NO. Second, normal downregulation of Ca(2+) channels by exogenous NO (sodium nitroprusside [SNP], 100 nmol/L) and cGMP (8-bromo-cGMP, 0.1 mmol/L) was absent, whereas normal upregulation of BK channels by these agents was preserved, suggesting block of NO signaling downstream of cGMP-dependent protein kinase. In pial window preparations, chronic nicotine blunted NO-induced vasodilation of pial vessels and the increase in cortical blood flow measured by laser-Doppler flowmetry, demonstrating the importance of Ca(2+) channel downregulation in NO-induced vasorelaxation. These findings elucidate a new pathophysiological mechanism involving altered Ca(2+) homeostasis in cerebral arterioles that may predispose to stroke.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / pharmacology
  • Animals
  • Arterioles / drug effects
  • Arterioles / physiology
  • Barium / pharmacology
  • Calcium / metabolism
  • Calcium Channels / physiology*
  • Calcium Channels, L-Type / physiology
  • Cerebral Arteries / drug effects*
  • Cerebral Arteries / physiology
  • Cerebrovascular Circulation / drug effects
  • Cyclic GMP / analogs & derivatives*
  • Cyclic GMP / pharmacology
  • Dihydropyridines / pharmacology
  • Electric Stimulation
  • Female
  • Membrane Potentials / drug effects
  • Muscle, Smooth, Vascular / cytology
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / physiology
  • Nicotine / pharmacology*
  • Nifedipine / pharmacology
  • Nitric Oxide / physiology*
  • Nitroprusside / pharmacology
  • Potassium Channels / physiology
  • Rats
  • Rats, Inbred WKY
  • Signal Transduction / drug effects
  • Time Factors
  • Tyrphostins / pharmacology

Substances

  • Calcium Channels
  • Calcium Channels, L-Type
  • Dihydropyridines
  • Potassium Channels
  • Tyrphostins
  • Nitroprusside
  • Barium
  • 8-bromocyclic GMP
  • Nitric Oxide
  • Nicotine
  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
  • 1,4-dihydropyridine
  • Cyclic GMP
  • Nifedipine
  • tyrphostin A23
  • Calcium